Phase I study of an antihyperlipidemic BAY w 6228 (cerivastatin sodium) (2): Results on multiple administration studies in healthy adult male volunteers

Japanese Pharmacology and Therapeutics

Volumn 24, Issue SUPPL. 9, 1996, Pages 37-53

  Azuma, Junichi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID METABOLISM; MALE; PHASE 1 CLINICAL TRIAL; VOLUNTEER;

EID: 0029854053     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Schmidt D : Comparison of the Inhibition of HMG-CoA-Reductase by various HMG-CoA-Reductase-Inhibitors. Bayer AG Report No. PH-24919, 1990
2. 14C] BAY w 6228 ; Biotransformation in rats. Bayer AG Report No. 24499, 1995
3. 14C] BAY w 6228 ; Biotransformation in Beagle Dogs. Bayer AG Report No. 22025 (P), 1992
4. 14C] BAY w 6228 ; Biotransformation in human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Bayer AG Report No. 24571 (P), 1995
5. Bischoff H : Effect of BAY w5679=M1 (metabolite of BAY w 6228) on hepatic cholesterol synthesis of rats after intravenous injection. Bayer AG Report No. 24599, 1995
6. Bischoff H : Effect of BAY 17-5111 (metabolite of BAY w 6228) on hepatic cholesterol synthesis of rats after intravenous injection. Bayer AG Report No. 24529, 1995
7. Bischoff H : Effect of BAY 19-3103 (metabolite of BAY w 6228) on hepatic cholesterol synthesis of rats after intravenous injection. Bayer AG Report No. 24528, 1995